| Literature DB >> 28704371 |
Mohamed A El-Brolosy1, Didier Y R Stainier1.
Abstract
Several recent studies in a number of model systems including zebrafish, Arabidopsis, and mouse have revealed phenotypic differences between knockouts (i.e., mutants) and knockdowns (e.g., antisense-treated animals). These differences have been attributed to a number of reasons including off-target effects of the antisense reagents. An alternative explanation was recently proposed based on a zebrafish study reporting that genetic compensation was observed in egfl7 mutant but not knockdown animals. Dosage compensation was first reported in Drosophila in 1932, and genetic compensation in response to a gene knockout was first reported in yeast in 1969. Since then, genetic compensation has been documented many times in a number of model organisms; however, our understanding of the underlying molecular mechanisms remains limited. In this review, we revisit studies reporting genetic compensation in higher eukaryotes and outline possible molecular mechanisms, which may include both transcriptional and posttranscriptional processes.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28704371 PMCID: PMC5509088 DOI: 10.1371/journal.pgen.1006780
Source DB: PubMed Journal: PLoS Genet ISSN: 1553-7390 Impact factor: 5.917
Glossary.
| Term | Definition |
|---|---|
| knockout | a genetic perturbation that aims to ablate gene function [ |
| knockdown | a perturbation at the DNA, RNA, or protein level that reduces the amount of functional RNA or protein [ |
| genetic compensation | changes in RNA or protein levels that can functionally compensate for the loss of function of another gene |
| transcriptional adaptation | changes in RNA levels that result from a genetic mutation and not from the loss of gene function |
Examples of discrepancies between mutant and knockdown phenotypes.
| Model organism | Gene | Mutant phenotype | Knockdown phenotype | Proposed compensating gene in mutants | Reference(s) |
|---|---|---|---|---|---|
| No obvious phenotype | Decreased cell expansion and division, causing a retardation in leaf growth | N/A | [ | ||
| Yeast | No profound defects | Defects in cell polarity and decreased cell viability | N/A | [ | |
| Zebrafish | Minor or no vascular defects | Severe vascular defects | [ | ||
| Mouse | No mitophagy defects in mouse liver following acetaminophen (APAP) treatment | Reduced mitophagy in mouse liver following APAP treatment | N/A | [ | |
| No obvious phenotype in astrocytes | Rearrangement of the filamentous actin cytoskeleton and downregulation of CX-43 in astrocytes | N/A | [ | ||
| mESCs maintain an undifferentiated morphology | mESCs lose their undifferentiated morphology | [ | |||
| Knockdown of | N/A | [ | |||
| Mutant mice do not develop hypoglycemia or hypertriglyceridemia under normal feeding conditions | Knockdown mice develop hypoglycemia and hypertriglyceridemia under normal feeding conditions | N/A | [ | ||
| No obvious phenotype in MEFs | Decreased ciliogenesis in MEFs | N/A | [ | ||
| Human | No proliferation defects in several breast cancer cell lines | Decreased proliferation in several breast cancer cell lines | N/A | [ |
Abbreviations: MEFs, mouse embryonic fibroblasts; mESCs, mouse embryonic stem cells; N/A, non-applicable
Fig 1Proposed models of transcriptional adaptation.
(A) DNA damage response can induce chromatin reorganization, increasing chromatin accessibility at the compensatory genes’ regulatory regions. (B) Mutations can lead to transcripts that are targeted for degradation through mRNA surveillance pathways. The resulting RNA fragments may trigger the compensatory response. As a secondary effect of the mutated gene’s mRNA degradation, RBPs or miRNAs normally acting on the mutated as well as the compensating genes’ mRNAs become more available to exert their stabilizing effects on the compensating genes’ mRNAs. Abbreviations: miRNAs, microRNAs; RBPs, RNA-binding proteins; TFs, transcription factors.